Nomura Asset Management Co. Ltd. Decreases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Nomura Asset Management Co. Ltd. decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,398 shares of the life sciences company’s stock after selling 6,195 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Illumina were worth $5,933,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. AKO Capital LLP bought a new stake in Illumina in the 4th quarter worth approximately $66,185,000. Norges Bank bought a new stake in Illumina in the fourth quarter worth $228,714,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Illumina in the fourth quarter worth $493,000. Elo Mutual Pension Insurance Co lifted its position in Illumina by 10.1% during the fourth quarter. Elo Mutual Pension Insurance Co now owns 15,581 shares of the life sciences company’s stock valued at $2,082,000 after purchasing an additional 1,431 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its position in Illumina by 169.6% during the fourth quarter. WINTON GROUP Ltd now owns 38,550 shares of the life sciences company’s stock valued at $5,151,000 after purchasing an additional 24,249 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on ILMN. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Piper Sandler lifted their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Canaccord Genuity Group reduced their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Robert W. Baird reduced their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Trading Down 0.8 %

ILMN opened at $79.34 on Tuesday. Illumina, Inc. has a 12 month low of $77.54 and a 12 month high of $156.66. The stock has a fifty day moving average price of $101.65 and a 200-day moving average price of $126.49. The firm has a market cap of $12.57 billion, a price-to-earnings ratio of -10.33, a PEG ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.